Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Kiadis Pharma (Netherlands), a clinical-stage biopharmaceutical company developing treatments for blood cancers, closed a $12.8M Series D financing. Participants include Life Sciences Partners, DFJ-Esprit, Alta Partners, Quest for Growth and NOM.

Pearl Therapeutics (Redwood City, CA), a clinical-stage pharmaceutical company focused on the development of therapeutics for respiratory diseases, closed a $65M Series D financing. Participants include Vatera Healthcare Partners, 5AM Ventures, Clarus Ventures and New Leaf Ventures. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate Access to Humankinds Most […]

Auspex Pharmaceuticals (La Jolla, CA), a clinical-stage pharmaceutical company focused on hyperkinetic movement disorders including Huntington’s disease, Tourette syndrome and tardive dyskinesia, closed a $25M Series D financing. Participants include Panorama Capital, Thomas, McNerney & Partners, CMEA Capital and Sloan Biotech Fund. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and […]

Promedior (Malvern, PA), a clinical-stage biotechnology company focused on Age-Related Macular Degeneration, closed a $3M Series D financing, bringing the total round to $24.5M. Participants include Shire Strategic Investment Group, Fibrotec Ventures, Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion Capital Partners and Easton Capital Investment Group. Collective IP | The Most Comprehensive and Accurate […]

Relievant Medsystems (Redwood City, CA) a clinical-stage medical device company focused on a device for radio frequency nerve ablation for chronic axial low back pain, closed a $30M Series D financing. Participants include New Enterprise Associates, Morgenthaler Ventures, Emergent Medical Partners, Canaan Partners and Onset Ventures.

AirXpanders (Palo Alto, CA) a clinical-stage biotechnology company focused on implantable breast tissue expanders for breast cancer masectomy patients, closed a $10M Series D financing. Participants include Vivo Ventures, GBS Venture Partners, Prolog Ventures, Heron Capital and Western Technology Innovation.

Natura (Redwood City, CA) a clinical-stage diagnostic company focused on non-invasive prenatal DNA diagnostic tests for gene translocations, aneuploidy, single genes and Down Syndrome, closed a $20M Series D financing. Participants include Lightspeed Venture Partners, Claremont Creek Ventures and Sequoia Capital.

Promedior (Malvern, PA) a clinical stage biotechnology company developing pentraxin therapeutics for fibroproliferative diseases, closed a $21.5M Series D financing. Participants include Fibrotec Ventures, Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion Capital Partners and Easton Capital Investment Group.

Celladon (La Jolla, CA), a clinical-stage biopharmaceutical company focused on cardiovascular diseases, closed a $43M Series D financing. Participants include Pfizer Venture Investments, Lundbeckfond Ventures, Novartis Venture Funds, H&Q Healthcare/Life Sciences Investors, GBS Venture Partners, Enterprise Partners Venture Capital, Johnson & Johnson Development Corporation and Venrock Associates.

Roka BioScience (Warren, NJ) a development-stage diagnostic company focused on molecular assays for monitoring food safety applications and biopharmaceutical manufacturing, closed a $27.5M Series D financing. Participants include Aisling Capital, OrbiMed, New Enterprise Associates and TPG Biotech.

MedVentive (Waltham, MA) a commercial-stage electronic medical data company focused on clinical integration, population management and financial risk management, closed a $12M Series D financing. Participants include National Healthcare Services, CHV Capital, Core Capital Partners, Excel Venture Management, HLM Venture Partners and Long River Ventures.

Advanced ICU Care (St Louis, MO) a commercial-stage Tele-ICU medical services company focused on bedside critical care, closed a $8M Series D financing. Participants include Trident Capital, Versant Ventures, Arboretum Ventures and Catalyst Capital.

Chromatin (Chicago, IL) a commercial-stage bioenergy market company focused on crop improvement and biomass feedstocks for the renewable energy sector closed a $10.4M Series D financing. Participants include BP Ventures, Unilever Technology Ventures, Quantitative Investment Holdings, Malaysian Life Sciences Capital Fund and Illinois Ventures.

« Previous Entries  Next Page »

to top of page...